---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002731"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:06:20.187143+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics elects Carlo Incerti, M.D. to Board of Directors

## Summary
- Dr. Incerti elected as Class I director, term expiring at 2024 annual meeting.
- Received option to purchase 39,139 shares at $8.69 per share (March 2 closing price).
- Option vests in equal monthly installments over three years; full acceleration on change of control.
- Annual cash compensation of $35,000 plus standard director equity grants and expense reimbursement.
- Board determined Dr. Incerti is an independent director under Nasdaq rules.

## SEC filing metadata
- accession: 0000950170-22-002731
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017022002731/0000950170-22-002731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017022002731/dyn-20220302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002731
- JSON: https://secwatch.observer/filing/0000950170-22-002731.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002731.txt

## Key facts
- Executive change
  Carlo Incerti was elected as Director at Dyne Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: On March 2, 2022, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Carlo Incerti, M.D. as a Class I director to serve on the Board until the Company’s 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017022002731/0000950170-22-002731-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.